ORGO Organogenesis Holdings Inc.
USHealthcareAs of 2026-07-10 11:36
Why ORGO matters now
Organogenesis Holdings Inc. (ORGO) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.39 with -2.85% on the session and $307.5M in market capitalization; recent performance reads 1-month +0.41% and YTD -52.90%.
The latest financial table shown here is Q1 2026, with revenue of $37.2M, net income of $-56.2M, and EPS of $-0.44. Investors can compare that operating picture with valuation signals such as P/E 7.85 and FCF yield 5.4%.
The latest indexable market news headline is "Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $3.00; recent insider activity includes Grow Brian filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
7.85
PEG
0.00
P/B
0.82
P/S
0.61
EV/EBITDA
7.85
DCF Value
$2.40
FCF Yield
5.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.4%
Operating Margin
2.1%
Net Margin
-0.1%
ROE
-0.1%
ROA
-0.1%
ROIC
-0.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $37.2M | $-56.2M | $-0.44 |
| Q4 2025 | $225.1M | $43.7M | $0.27 |
| FY 2025 | $563.0M | $37.0M | $0.15 |
| Q3 2025 | $150.5M | $21.6M | $0.11 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$3.00
Target (Median)
$3.00
Target Range
$3.00 - $3.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
1.33
Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.